ArticlePragmatic and observational research2020
The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial Results.
Article in Pragmatic and observational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03373045 (The CHRONICLE Study), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States
Who cites it
22 citing papers in PubMed, 23 citations in OpenAlex.
- Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study.Advances in therapy · 2025Trial
- Biologic effectiveness increases with earlier biologic initiation after severe asthma onset.The journal of allergy and clinical immunology. Global · 2026Article
- Incidence of New Malignancies in Severe Asthma: Comparison of Real-World Patients Treated with Benralizumab, Other Biologics, or Non-biologics.Pulmonary therapy · 2026Article
- Observational
- Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study.Respiratory research · 2026Observational
- Asthma biologic effectiveness by age and sex in the US CHRONICLE study.The journal of allergy and clinical immunology. Global · 2026Article
- Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study.The journal of allergy and clinical immunology. Global · 2026Article
- Mortality Among Adults with Subspecialist-Treated Severe Asthma: A Descriptive Analysis from the Observational CHRONICLE Study.Journal of asthma and allergy · 2026Article
- Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- On-treatment clinical remission of severe asthma with real-world longer-term biologic use.The journal of allergy and clinical immunology. Global · 2025Article
- INSIGHTS Asthma Pragmatic Registry - A Pragmatic Approach to High-Validity Real-World Evidence for Asthma.Pragmatic and observational research · 2025Article
- Clinical Remission in Patients Affected by Severe Eosinophilic Asthma on Dupilumab Therapy: A Long-Term Real-Life Study.Journal of clinical medicine · 2024Article
- Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE Study.Journal of asthma and allergy · 2024Article
- Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.Journal of asthma and allergy · 2024Review
- Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe Asthma.Journal of asthma and allergy · 2024Article
- Adult Severe Asthma Registries: A Global and Growing Inventory.Pragmatic and observational research · 2023Article
- A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma.Advances in therapy · 2022Article
- The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma.The Korean journal of internal medicine · 2022Review
- Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.Journal of asthma and allergy · 2022Article
- Long-Term Use of Maintenance Systemic Corticosteroids is Associated with Multiple Adverse Conditions in a Large, Real-World Cohort of US Adults with Severe Asthma.Journal of asthma and allergy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundApproximately 5-10% of patients with asthma have severe disease. High-quality real-world studies are needed to identify areas for improved management.
objectiveAligned with the International Severe Asthma Registry, the CHRONICLE study (ClinicalTrials.gov: NCT03373045) was developed to address this need in the US. STUDY
designLearnings from prior studies were applied to develop a real-world, prospective, noninterventional study of US patients with confirmed severe asthma who are treated by subspecialist physicians and require biologic or maintenance systemic immunosuppressant therapy or who are uncontrolled by high-dosage inhaled corticosteroids and additional controllers. Target enrollment is 4000 patients, with patient observation for ≥3 years. A geographically diverse sample of allergist/immunologist and pulmonologist sites approach all eligible patients under their care and report patient characteristics, treatment, and health outcomes every 6 months. Patients complete online surveys every 1-6 months. INITIAL
resultsFrom February 2018 to February 2019, 102 sites screened 1428 eligible patients; 936 patients enrolled. Study sites (40% allergist/immunologist, 42% pulmonologist, 18% both) were similar to other US asthma subspecialist samples. Enrolled patients were 67% female with median ages at enrollment and diagnosis of 55 (range: 18-89) and 26 (0-80) years, respectively. Median body mass index was 31 kg/m
conclusionCHRONICLE will provide high-quality provider- and patient-reported data from a large, real-world cohort of US adults with subspecialist-treated severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.